News

Reagan Udall Foundation for the US Food and Drug Administration (FDA), a non-profit organization created by Congress, hosted the hybrid public meeting “Advancing Treatments for Post-Traumatic Stress Disorder” on September 6, 2024.

On Wednesday, the FDA issued a Constituent Update detailing efforts to enhance food traceability. Deputy Commissioner Jim Jones highlighted the FDA’s online resources regarding the Food Traceability Rule, as well as roundtables with the Reagan-Udall…

FMI – The Food Industry Association has expressed its support for the process set forth by the U.S. Food and Drug Administration (FDA) and the nonprofit Reagan-Udall Foundation to solicit feedback from stakeholders about the challenges involved in…

Subsequently, the Reagan-Udall Foundation was contracted by the FDA to conduct a series of three invitation-only industry stakeholder meetings focused on FSMA 204 implementation challenges. IFPA attended all of these.

“This is like the weight-loss clinic,” Jenni Wai, Ohio’s chief pharmacist, said of ketamine providers at a June workshop held by the Reagan-Udall Foundation, a congressionally created nonprofit that advises the FDA. “This is like the med spas and the…

“The Supreme Court’s decision elevates the importance of the Reagan-Udall Foundation’s findings after being convened at the request of the FDA commissioner, which specifically and clearly criticized the FDA’s Center for Tobacco Products for failing to…

The meeting, which will be facilitated by the Reagan-Udall Foundation, will provide those in the rare disease community the opportunity to provide input on the priorities of the hub. The FDA plans for the hub to work across rare diseases but especially…

On Monday, the FDA announced that it will hold a public meeting on October 16, 2024, titled, “Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub.” Read more

According to findings by the Reagan Udall Foundation, that is exactly what is happening as stakeholders navigating the process “expressed concerns about a lack of clarity, transparency, and communication” regarding the CTP’s priorities and decision-…

FDA draft guidance posted in June 2023 provides a potential framework on how to overcome expectancy bias and the nocebo effect by employing an active placebo which could be a substance that also has mind-altering effects but no expected therapeutic…